

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33614> holds various files of this Leiden University dissertation.

**Author:** Lehmann, Kathleen Corina

**Title:** Biochemistry and function of nidovirus replicase proteins

**Issue Date:** 2015-06-23

## 1 SUMMARY

2  
3 The order Nidovirales comprises a monophyletic group of viruses with positive-stranded  
4 RNA genomes that are classified in the families *Arteriviridae*, *Coronaviridae*, *Mesoniviridae*,  
5 and *Roniviridae*. They share a conserved genome organization and a characteristic set  
6 of key replicative proteins. Although, in principle, this suggests a conserved replication  
7 mechanism, it is currently unclear how far exactly the resemblance extends on a more  
8 detailed level. This is foremost due to our poor understanding of the role of most viral  
9 proteins in the replication cycle. In addition, most of the knowledge that was obtained  
10 predominantly derives from studies of only few coronaviruses, the nidovirus subgroup  
11 with the largest known genome and therefore presumably employing the most complex  
12 replication strategy. In contrast, thus far only limited attention was given to the RNA rep-  
13 licating and processing enzymes of arteriviruses, and none at all to those of mesoni- and  
14 roniviruses, whose genome sizes are (much) smaller than those of coronaviruses. Given  
15 this disparity, it may be premature to assume that within this divergent group of viruses  
16 essential steps of the viral replication cycle, like for example RNA synthesis and mRNA  
17 5' end modification, strictly follow the same mechanistic pathways.

18  
19 The work described in this thesis addresses some poorly or uncharacterized (domains  
20 of) nonstructural proteins (nsps) that are likely involved in one or multiple steps of  
21 RNA replication and/or transcription of the prototypic arterivirus equine arteritis virus  
22 (EAV). After a short introduction on the nidovirus replication cycle and our knowledge  
23 of the molecular details of the unusual transcription and mRNA processing mechanism  
24 (chapter 1), chapter 2 presents the crystal structure of the enzymatically active EAV  
25 helicase nsp10, which was obtained and analyzed in close collaboration with Chinese  
26 colleagues. Interestingly, a strong resemblance between this viral protein and the con-  
27 served cellular helicase Upf1, in particular with respect to their N-terminal zinc-binding  
28 domains, became obvious. Since this cellular helicase has been implicated in a number  
29 of eukaryotic post-transcriptional quality control mechanisms, a role for nsp10 and its  
30 nidovirus homologs in genome expansion is proposed. This and other potential func-  
31 tions of the nidovirus helicase in RNA replication, transcription, and translation, as well  
32 as virion biogenesis are further discussed in chapter 3, which presents a review of our  
33 current knowledge about nidovirus helicases. Special emphasis is placed on gaps that  
34 still remain, facts that cannot be easily reconciled with our current understanding of the  
35 nidovirus replication mechanisms, and questions that need to be addressed in future.

36  
37 Chapters 4 and 5 focus on one of the central arterivirus replication proteins, nsp9, which  
38 harbors the RNA-dependent RNA polymerase (RdRp) domain. Chapter 4 describes a care-  
39 fully controlled study to investigate different polymerase activities that nsp9 may have,

1 including a previously claimed primer-independent RdRp activity. Despite considerable  
2 efforts, involving experiments with different preparations of nsp9 and assays performed  
3 in the presence of putative polymerase co-factors, no *in vitro* activity was observed that  
4 could be clearly attributed to this protein. Moreover, circumstantial evidence suggested  
5 that the previously reported activity may have been caused by a contamination of the  
6 recombinant nsp9 preparation with the T7 RNA polymerase used to drive its expression  
7 in *E. coli*. In arteriviruses, the RdRp domain is located in the C-terminal two-thirds of nsp9.  
8 In chapter 5, it is now described for the first time that the RdRp domain is flanked at its  
9 N-terminus by another domain that is conserved in all nidoviruses. However, unlike the  
10 situation for the RdRp domain, no homologs of this domain have been found in other  
11 RNA viruses. This domain is thus proposed to be a second marker for the *Nidovirales*  
12 order, besides the N-terminal zinc-binding domain of the helicase subunit. Residues that  
13 are part of three conserved sequence motifs were without exception associated with  
14 a newly discovered nucleotidylation activity of recombinant nsp9. It is thus proposed  
15 that this activity could play a role in the modification of the 5' end of viral RNAs through  
16 either RNA ligation, protein priming of RNA synthesis, or guanylyl transfer during mRNA  
17 capping. Further research is required to definitely tie nsp9 to one of these pathways.  
18 Nevertheless, alanine substitution of any of these conserved residues was either lethal  
19 to EAV and severe acute respiratory syndrome coronavirus (SARS-CoV) or severely  
20 crippled these viruses, eventually resulting in reversion of the mutation. These results  
21 thus demonstrate the essential nature of this domain for virus replication, whatever its  
22 exact function will turn out to be.

23  
24 Two methyltransferase activities, commonly required for capping of mRNAs, were  
25 previously identified in two ORF1b-encoded coronavirus proteins, nsp14 and nsp16.  
26 While the former has no counterpart among the arterivirus nonstructural proteins, the  
27 latter and the arterivirus C-terminal subunit nsp12 occupy equivalent positions in the  
28 ORF1b-encoded part of the replicase although the two proteins share no detectable  
29 sequence similarity. It is thus a long standing question, how arteriviruses may catalyze  
30 the 5' end modification of mRNAs, and we therefore performed a first characterization of  
31 the entirely uncharacterized EAV nsp12 subunit (chapter 6). Based on the genomic posi-  
32 tion of its coding sequence, sequence alignment, and secondary structure prediction, it  
33 is hypothesized that nsp12 might represent a unique arterivirus methyltransferase that  
34 has diverged from its homologs beyond sharing appreciated similarity. To test this hy-  
35 pothesis, recombinant nsp12 was expressed in and purified from *E. coli* and tested alone  
36 and in combination with potential co-factors for N7- and 2'-O-methyltransferase activ-  
37 ity. Although positive controls represented by the SARS-CoV methyltransferases (nsp14  
38 and the nsp10:nsp16 complex) demonstrated the functionality of the assay, no activity  
39 was detected for EAV nsp12. Guided by the sequence alignment, an extensive set of EAV

1 mutants was generated and characterized with respect to their plaque phenotype and  
2 progeny titer, as well as their protein expression. These reverse genetics experiments  
3 revealed a number of phenotypes ranging from wild-type-like via non-spreading to  
4 replication-incompetent, which indicated that nsp12 is essential for viral replication.

5  
6 The above chapters describing biochemical properties of selected proteins may ulti-  
7 mately contribute to the identification of drug targets to combat nidovirus infections. In  
8 chapter 7 the prerequisites under which the marketing of such an antiviral drug would  
9 be economically viable are analyzed. This project was realized under guidance of several  
10 specialists of one of the industrial partners, Janssen Infectious Diseases, of the EUVIRNA  
11 consortium, the Marie Curie Initial Training Network to which my research project be-  
12 longed. This study concludes that, at the moment, none of the circulating nidoviruses  
13 constitutes a sufficiently sized market to warrant the considerable investments required  
14 for drug development. The situation may be different if a new highly-pathogenic virus  
15 would emerge, as exemplified in 2002 by SARS-CoV or 2012 by MERS-CoV. In view of  
16 such threats, pre-pandemic drug stockpiling could be considered. However, also under  
17 those circumstances, it seems likely that the inherent financial risk would preclude an in-  
18 dependent private initiative, even though market parameters and approval procedures  
19 appear to be favorable.

20  
21 Finally, chapter 8 connects some of the main findings described in this thesis with  
22 previously described data. In particular, potential differences between small and large  
23 nidoviruses on the level of the molecular mechanisms of RNA synthesis initiation and  
24 mRNA capping are highlighted. To this end, alternative mechanisms are considered that  
25 would be consistent with the data on arteriviruses presented in this thesis and else-  
26 where. Furthermore, potential roles of cellular helicases in nidovirus replication and the  
27 host's immune response against nidoviruses are discussed.

